Last Updated: 16 Oct 2024
Executive Summary
CRISPR Therapeutics AG (CRSP) is a gene editing company focused on developing transformative gene-based drugs for serious human diseases. With a market capitalization of $4.07 billion, CRSP has a strong presence in the life sciences sector. Despite negative earnings and profitability metrics, analysts remain optimistic about the company's long-term prospects.
Company Overview
Headquartered in Zug, Switzerland, CRSP leverages CRISPR technology to develop therapies for various diseases. The company's pipeline includes treatments for sickle cell disease, beta-thalassemia, and cancer. CRSP has collaborations with leading pharmaceutical companies such as Vertex Pharmaceuticals and Bayer.
Fundamental Analysis
CRSP's financial performance has been challenged in recent quarters. The company reported a loss per share of $3.2 in the latest quarter, with negative EBITDA and operating margins. However, revenue growth remains positive, albeit decelerating. Analysts note that CRSP's expenses are primarily driven by research and development, which is essential for its long-term growth.
Key financial metrics:
Revenue: $202.2 million TTM
Gross Profit: -$570.7 million TTM
Diluted EPS: -$3.2 TTM
Market Capitalization: $4.07 billion
Book Value: $23.29
Technical Analysis
CRSP's stock price has been volatile in recent months, trading within a range of $37.55 to $91.1. The 50-day moving average of $47.17 provides support, while the 200-day moving average of $59.21 acts as resistance. The beta of 1.672 indicates that CRSP's stock is more volatile than the broader market.
Short Term Outlook
Analysts expect CRSP's stock to remain range-bound in the short term. The company's upcoming clinical data readouts and regulatory updates will be key catalysts for price movement. If positive, these events could push the stock above the 200-day moving average.
Long Term Outlook
Analysts are bullish on CRSP's long-term prospects. The company's innovative technology has the potential to revolutionize the treatment of serious diseases. As CRSP advances its pipeline and secures regulatory approvals, its revenue and profitability are expected to improve.
Analyst Recommendations
Analysts have varying ratings on CRSP:
Strong Buy: 6
Buy: 8
Hold: 12
Sell: 3
Strong Sell: 0
The consensus analyst target price is $80.92, implying a potential upside of 68.4% from the current price of $48.05.
